Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey

Virchows Arch. 2017 Dec;471(6):809-813. doi: 10.1007/s00428-017-2222-z. Epub 2017 Aug 25.

¹ UK NEQAS for Molecular Genetics, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh, EH16 4SA, UK. sandi.deans@ed.ac.uk.
² UK NEQAS for Molecular Genetics, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Little France Crescent, Edinburgh, EH16 4SA, UK.
³ Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, KU Leuven / University Hospital of Leuven, Leuven, Belgium.
⁴ Biomedical Quality Assurance Research Unit, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
⁵ Cell Biology and Biotherapy Unit, Instituto Nazionale Tumouri "Fondazione Giovanni Pascale", IRCCS, Naples, Italy.
⁶ Department of Pathology, University of Groningen, University Medical Center of Groningen, Groningen, The Netherlands.
⁷ European Molecular Genetics Quality Network, Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, M13 9WL, UK.
⁸ All Wales Genetic Laboratory, Institute of Medical Genetics, University Hospital of Wales, Heath Park, Cardiff, CF14 4XW, UK.
⁹ International Quality Network for Pathology (IQN Path ASBL), 3A Sentier de l'Esperance, L-1474, Luxembourg, Luxembourg.
¹⁰ Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.

No abstract available

MeSH terms